$IMMU: Immunomedics highlights clinical pipeline for solid cancer and lupus therapy at R&D day (4.30 -0.27)
An update of 42 patients who had computed tomography (CT) scans following their therapy with IMMU-132 was presented by Dr. Alexander N. Starodub, medical oncologist and Director of Clinical Research at Indiana University Health Goshen Center for Cancer Care, in Goshen, IN. "The most exciting observation so far," Dr. Starodub stated, "is that a high percentage of patients with advanced disease are showing high rates of disease control, with the most impressive results in triple-negative breast cancer and small-cell lung cancer patients. These cancers are very difficult to treat, especially after failing other therapies, so it is unusual to see 2 of 7 patients with triple-negative breast cancer and 2 of 4 patients with small-cell lung cancer showing partial responses by computed tomography, or RECIST criteria. A 67% response rate, with one partial response and 9 with stable disease, also was achieved in advanced colorectal cancer patients," he added. Dr. Starodub further emphasized that "a time-to-progression plot of responders shows that many are of long duration, even up to almost a year in some cases, which is most encouraging in this population of patients with advanced solid cancers that have relapsed after multiple prior therapies."
Results of 13 pancreatic cancer patients with CT-assessments were not included in Dr. Starodub's update but will be presented at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Innovations in Research and Treatment on Tuesday, May 20, 2014.
Sheff's Station...All Aboard...Sign Up Here!
